

# HOUSE BILL 674

E4, J1

01r0100

---

By: **Chair, Judiciary Committee (By Request – Departmental – Health)**

Introduced and read first time: January 29, 2020

Assigned to: Judiciary

---

## A BILL ENTITLED

1 AN ACT concerning

2 **Controlled Dangerous Substances – Schedules**

3 FOR the purpose of altering the lists of substances designated as controlled dangerous  
4 substances under certain schedules under the Maryland Controlled Dangerous  
5 Substances Act; making stylistic changes; and generally relating to schedules for  
6 controlled dangerous substances.

7 BY repealing and reenacting, with amendments,  
8 Article – Criminal Law  
9 Section 5–402 through 5–406  
10 Annotated Code of Maryland  
11 (2012 Replacement Volume and 2019 Supplement)

12 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND,  
13 That the Laws of Maryland read as follows:

14 **Article – Criminal Law**

15 5–402.

16 (a) Schedule I consists of each controlled dangerous substance:

17 (1) listed in this section;

18 (2) added to Schedule I by the Department under § 5–202(b) of this title; or

19 (3) designated as a Schedule I controlled dangerous substance by the  
20 federal government unless the Department objects under § 5–202(f) of this title.

21 (b) Unless specifically excepted under this subtitle or listed in another schedule,  
22 any of the following opiates, including their isomers, including optical and geometric

---

EXPLANATION: CAPITALS INDICATE MATTER ADDED TO EXISTING LAW.

[Brackets] indicate matter deleted from existing law.



1 isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the  
 2 existence of such isomers, esters, ethers, or salts is possible within the specific chemical  
 3 designation, are substances listed in Schedule I:

4 (1) [acetyl-alpha-methylfentanyl] ACETYL-ALPHA-METHYLFENTANYL  
 5 (*N*-[1-(1-METHYL-2-PHENETHYL)-4-PIPERIDINYL]-*N*-PHENYLACETAMIDE);

6 (2) acetylmethadol;

7 (3) [acetyl fentanyl  
 8 (n-(1-phenethylpiperidine-4-yl)-n-phenylacetamide)] ACETYL FENTANYL  
 9 (*N*-[1-PHENETHYLPYPERIDIN-4-YL]-*N*-PHENYLACETAMIDE);

10 (4) ACRYL FENTANYL  
 11 (*N*-[1-PHENETHYLPYPERIDIN-4-YL]-*N*-PHENYLACRYLAMIDE);

12 (5) [ah-7921  
 13 (3,4-dichloro-n-[(1-dimethylamino)cyclohexylmethyl])benzamide] AH-7921  
 14 (3,4-DICHLORO-*N*-[(1-DIMETHYLAMINO) CYCLOHEXYLMETHYL]) BENZAMIDE;

15 [(5)] (6) allylprodine;

16 [(6)] (7) alphacetylmethadol, except [levoalphacetylmethadol]  
 17 LEVO-ALPHACETYLMETHADOL;

18 [(7)] (8) alphameprodine;

19 [(8)] (9) alphamethadol;

20 [(9)] (10) [alpha-methylfentanyl] ALPHA-METHYLFENTANYL  
 21 (*N*-[1-(ALPHA-METHYL-BETA-PHENYL)ETHYL-4-PIPERIDYL] PROPIONANILIDE;  
 22 1-(1-METHYL-2-PHENYLETHYL)-4-(*N*-PROPANILIDO) PIPERIDINE);

23 [(10)] (11) [alpha-methylthiofentanyl] ALPHA-METHYLTHIOFENTANYL  
 24 (*N*-[1-METHYL-2-(2-THIENYL)ETHYL-4-PIPERIDINYL]-*N*-  
 25 PHENYLPROPANAMIDE);

26 [(11)] (12) benzethidine;

27 [(12)] (13) betacetylmethadol;

28 [(13)] (14) [beta-hydroxyfentanyl] BETA-HYDROXYFENTANYL  
 29 (*N*-[1-(2-HYDROXY-2-PHENETHYL)-4-PIPERIDINYL]-*N*-PHENYLPROPANAMIDE);

30 [(14)] (15) beta-hydroxy-3-methylfentanyl;



- 1            [(31)] **(36)** furethidine;
- 2            [(32)] **(37)** hydroxypethidine;
- 3            [(33)] **(38)** ketobemidone;
- 4            [(34)] **(39)** levomoramide;
- 5            [(35)] **(40)** levophenacymorphan;
- 6            [(36)] **(41)** [3-methylfentanyl  
7 (n-3-methyl-1-(2-phenylethyl)-4-piperidyl-1-n-phenylpropanamide)]  
8 **3-METHYLFENTANYL (N-[3-METHYL-1-(2-PHENYLETHYL)-4-PIPERIDYL]-N-**  
9 **PHENYLPROPANAMIDE)**;
- 10           [(37)] **(42)** 3-methylthiofentanyl;
- 11           [(38)] **(43)** morpheridine;
- 12           [(39)] **(44)** MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
- 13           **(45) MT-45 (1-CYCLOHEXYL-4-(1,2-DIPHENYLETHYL)PIPERAZINE)**;
- 14           [(40)] **(46)** noracymethadol;
- 15           [(41)] **(47)** norlevorphanol;
- 16           [(42)] **(48)** normethadone;
- 17           [(43)] **(49)** norpipanone;
- 18           **(50) OCFENTANIL (N-(2-FLUOROPHENYL)-2-METHOXY-N-(1-**  
19 **PHENETHYLPIPERIDIN-4-YL)ACETAMIDE)**;
- 20           [(44)] **(51)** para-fluorofentanyl        **(N-(4-FLUOROPHENYL)-N-[1-(2-**  
21 **PHENETHYL)-4-PIPERIDINYL] PROPANAMIDE)**;
- 22           [(45)] **(52)** PEPAP        [(1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine)]  
23 **(1-(2-PHENETHYL)-4-PHENYL-4-ACETOXYPIPERIDINE)**;
- 24           [(46)] **(53)** phenadoxone;
- 25           [(47)] **(54)** phenampromide;
- 26           [(48)] **(55)** phenomorphan;

1 [(49)] (56) phenoperidine;

2 [(50)] (57) piritramide;

3 [(51)] (58) proheptazine;

4 [(52)] (59) properidine;

5 [(53)] (60) propiram;

6 [(54)] (61) racemoramide;

7 (62) TETRAHYDROFURANYL FENTANYL  
 8 (*N*-(1-PHENETHYLPIPERIDIN-4-YL)-*N*-PHENYLTETRAHYDROFURAN-2-  
 9 CARBOXAMIDE);

10 [(55)] (63) thiofentanyl;

11 [(56)] (64) tilidine; [and]

12 [(57)] (65) [trimeperidin] TRIMEPERIDINE; AND

13 (66) U-47700  
 14 (3,4-DICHLORO-*N*-[2-(DIMETHYLAMINO)CYCLOHEXYL]-*N*-METHYLBENZAMIDE).

15 (c) Unless specifically excepted under this subtitle or listed in another schedule,  
 16 any of the following opium derivatives, including their salts, isomers, and salts of isomers,  
 17 whenever the existence of such salts, isomers, or salts of isomers is possible within the  
 18 specific chemical designation, are substances listed in Schedule I:

19 (1) acetorphine;

20 (2) acetyldihydrocodeine;

21 (3) benzylmorphine;

22 (4) codeine methylbromide;

23 (5) codeine-*N*-oxide;

24 (6) cyprenorphine;

25 (7) desomorphine;

26 (8) dihydromorphine;

- 1 (9) drotebanol;
- 2 (10) etorphine (except hydrochloride salt);
- 3 (11) heroin;
- 4 (12) hydromorphenol;
- 5 (13) methyldesorphine;
- 6 (14) methyldihydromorphine;
- 7 (15) morphine methylbromide;
- 8 (16) morphine methylsulfonate;
- 9 (17) morphine-N-oxide;
- 10 (18) myrophine;
- 11 (19) nicocodeine;
- 12 (20) nicomorphine;
- 13 (21) normorphine;
- 14 (22) pholcodine; and
- 15 (23) thebacon.

16 (d) Unless specifically excepted under this subtitle or listed in another schedule,  
17 any material, compound, mixture, or preparation that contains any quantity of the  
18 following hallucinogenic substances, or that contains any of its salts, isomers, including  
19 optical, position, and geometric isomers, or salts of isomers, whenever the existence of such  
20 salts, isomers, or salts of isomers is possible within the specific chemical designation, is a  
21 substance listed in Schedule I:

- 22 (1) alpha-ethyltryptamine;
- 23 (2) 4-bromo-2,5-dimethoxy-amphetamine;
- 24 (3) 4-bromo-2,5-dimethoxyphenethylamine;
- 25 (4) 2,5-dimethoxyamphetamine;
- 26 (5) 2,5-dimethoxy-4-ethylamphetamine (DOET);

- 1 (6) [2,5-dimethoxy-4-(n)-propylthiophenethylamine (2c-t-7)]  
2 **2,5-DIMETHOXY-4-(N)-PROPYLTHIOPHENETHYLAMINE (2C-T-7);**
- 3 (7) 4-methoxyamphetamine (PMA);
- 4 (8) 5-methoxy-3,4-methylenedioxy-amphetamine;
- 5 (9) 4-methyl-2,5-dimethoxy-amphetamine;
- 6 (10) 3,4-methylenedioxy amphetamine;
- 7 (11) 3,4-methylenedioxymethamphetamine (MDMA);
- 8 (12) [3,4-methylenedioxy-n-ethylamphetamine]  
9 **3,4-METHYLENEDIOXY-N-ETHYLAMPHETAMINE (MDA);**
- 10 (13) [n-hydroxy-3,4-methylenedioxyamphetamine]  
11 **N-HYDROXY-3,4-METHYLENEDIOXYAMPHETAMINE;**
- 12 (14) 3,4,5-trimethoxyamphetamine;
- 13 (15) [5-methoxy-n, n-dimethyltryptamine]  
14 **5-METHOXY-N, N-DIMETHYLTRYPTAMINE;**
- 15 (16) alpha-methyltryptamine (AMT);
- 16 (17) bufotenine;
- 17 (18) diethyltryptamine (DET);
- 18 (19) dimethyltryptamine (DMT);
- 19 (20) [5-methoxy-n, n-diisopropyltryptamine (5-MEO-DIPT)]  
20 **5-METHOXY-N, N-DIISOPROPYLTRYPTAMINE (5-MEO-DIPT);**
- 21 (21) ibogaine;
- 22 (22) lysergic acid diethylamide;
- 23 (23) marijuana;
- 24 (24) mescaline;
- 25 (25) [parahehyl] **PARAHEXYL-7374;**

- 1 (26) peyote (meaning all parts of the plant presently classified botanically  
 2 as *Lophophora williamsii* lemaire, whether growing or not, the seeds thereof, any extract  
 3 from any part of such plant, and every compound, manufacture, salt, derivative, mixture,  
 4 or preparation of such plant, its seeds, or extracts);
- 5 (27) [n-ethyl-3-piperidyl benzilate] **N-ETHYL-3-PIPERIDYL**  
 6 **BENZILATE;**
- 7 (28) [n-methyl-3-piperidyl benzilate] **N-METHYL-3-PIPERIDYL**  
 8 **BENZILATE;**
- 9 (29) psilocybin;
- 10 (30) psilocyn;
- 11 (31) tetrahydrocannabinols;
- 12 (32) ethylamine analog of phencyclidine  
 13 (N-ethyl-1-phenylcyclohexylamine);
- 14 (33) pyrrolidine analog of phencyclidine  
 15 (1-(1-phenylcyclohexyl)-pyrrolidine);
- 16 (34) [thiophene analog of phencyclidine  
 17 (1-(1-(2-thienyl)-cyclohexyl)-piperidine)] **THIOPHENE ANALOG OF PHENCYCLIDINE**  
 18 **(1-[1-(2-THIENYL)-CYCLOHEXYL]-PIPERIDINE);**
- 19 (35) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine;
- 20 (36) **4-METHYLMETHCATHINONE (MEPHEDRONE);**
- 21 **(37)** 3, 4-methylenedioxyprovalerone (MDPV);
- 22 [(37) 4-methylmethcathinone (mephedrone);
- 23 (38) 4-methoxymethcathinone (methedrone);]
- 24 [(39) **(38)** [2-(2,5-dimethoxy-4-ethylphenyl) ethanamine (2c-e)]  
 25 **2-(2,5-DIMETHOXY-4-ETHYLPHENYL) ETHANAMINE (2C-E);**
- 26 [(40) **(39)** [2-(2,5-dimethoxy-4-methylphenyl) ethanamine (2c-d)]  
 27 **2-(2,5-DIMETHOXY-4-METHYLPHENYL) ETHANAMINE (2C-D);**
- 28 [(41) **(40)** [2-(4-chloro-2,5-dimethoxyphenyl) ethanamine (2c-c)]  
 29 **2-(4-CHLORO-2,5-DIMETHOXYPHENYL) ETHANAMINE (2C-C);**

1                    [(42)] (41) [2-(4-iodo-2,5-dimethoxyphenyl) ethanamine (2c-i)]  
 2 **2-(4-IODO-2,5-DIMETHOXYPHENYL) ETHANAMINE (2C-I);**

3                    [(43)] (42) [2-(4-ethylthio-2,5-dimethoxyphenyl) ethanamine (2c-t-2)]  
 4 **2-[4-(ETHYLTHIO)-2,5-DIMETHOXYPHENYL] ETHANAMINE (2C-T-2);**

5                    [(44)] (43) [2-(4-isopropylthio)-2,5-dimethoxyphenyl) ethanamine  
 6 (2c-t-4)] **2-[4-(ISOPROPYLTHIO)-2,5-DIMETHOXYPHENYL] ETHANAMINE (2C-T-4);**

7                    [(45)] (44) [2-(2,5-dimethoxyphenyl) ethanamine (2c-h)]  
 8 **2-(2,5-DIMETHOXYPHENYL) ETHANAMINE (2C-H);**

9                    **(45) 2-(2,5-DIMETHOXY-4-NITRO-PHENYL) ETHANAMINE (2C-N);**

10                   (46) [2-(2,5-dimethoxy-4-(n)-propylphenyl) ethanamine (2c-p)]  
 11 **2-(2,5-DIMETHOXY-4-(N)-PROPYLPHENYL) ETHANAMINE (2C-P);**

12                   (47) [3,4-methylenedioxy-methcathinone (methydone)]  
 13 **3,4-METHYLENEDIOXY-N-METHYLCATHINONE (METHYLONE);**

14                   (48) [(1-pentyl-1h-indol-3-yl) (2,2,3,3-tetramethylcyclopropyl)  
 15 methanone (ur-144)] **(1-PENTYL-1H-INDOL-3-YL)**  
 16 **(2,2,3,3-TETRAMETHYLCYCLOPROPYL) METHANONE (UR-144);**

17                   (49) [[1-(5-fluoro-pentyl)-1h-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)  
 18 methanone (5-fluoro-ur-144, xlr11)]  
 19 **[1-(5-FLUORO-PENTYL)-1H-INDOL-3-YL](2,2,3,3-TETRAMETHYLCYCLOPROPYL)**  
 20 **METHANONE (5-FLUORO-UR-144, XLR11);**

21                   (50) [n-(1-adamantyl)-1-pentyl-1h-indazole-3-carboxamide (apinaca,  
 22 akb48)] **N-(1-ADAMANTYL)-1-PENTYL-1H-INDAZOLE-3-CARBOXAMIDE**  
 23 **(APINACA, AKB48);**

24                   (51) [quinolin-8-yl 1-pentyl-1h-indole-3-carboxylate (pb-22)]  
 25 **QUINOLIN-8-YL 1-PENTYL-1H-INDOLE-3-CARBOXYLATE (PB-22);**

26                   (52) [quinolin-8-yl 1-(5-fluoropentyl)-1h-indole-3-carboxylate  
 27 (5-fluoro-pb-22)] **QUINOLIN-8-YL**  
 28 **1-(5-FLUOROPENTYL)-1H-INDOLE-3-CARBOXYLATE (5-FLUORO-PB-22);**

29                   (53)  
 30 [n-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1h-indazole-3-  
 31 carboxamide (ab-fubinaca)]

1 *N*-(1-AMINO-3-METHYL-1-OXOBUTAN-2-YL)-1-(4-FLUOROBENZYL)-1*H*-  
 2 INDAZOLE-3-CARBOXAMIDE (AB-FUBINACA);

3 (54) [n-(1-amino-3,  
 4 3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1*H*-indazole-3-carboxamide (adb-pinaca)]  
 5 *N*-(1-AMINO-3,  
 6 3-DIMETHYL-1-OXOBUTAN-2-YL)-1-PENTYL-1*H*-INDAZOLE-3-CARBOXAMIDE  
 7 (ADB-PINACA);

8 (55) [2-(4-iodo-2,5-dimethoxyphenyl)-n-(2-methoxybenzyl) ethanamine  
 9 (25I-nbome)] 2-(4-iodo-2,5-DIMETHOXYPHENYL)-*N*-(2-METHOXYBENZYL)  
 10 ETHANAMINE (25I-NBOME);

11 (56) [2-(4-chloro-2,5-dimethoxyphenyl)-n-(2-methoxybenzyl)  
 12 ethanamine (25C-nbome)]  
 13 2-(4-CHLORO-2,5-DIMETHOXYPHENYL)-*N*-(2-METHOXYBENZYL) ETHANAMINE  
 14 (25C-NBOME);

15 (57) [2-(4-bromo-2,5-dimethoxyphenyl)-n-(2-methoxybenzyl)  
 16 ethanamine (25B-nbome)]  
 17 2-(4-BROMO-2,5-DIMETHOXYPHENYL)-*N*-(2-METHOXYBENZYL) ETHANAMINE  
 18 (25B-NBOME);

19 (58) marijuana extract (meaning an extract containing one or more  
 20 cannabinoids that has been derived from any plant of the genus cannabis, other than the  
 21 separated resin, whether crude or purified, obtained from the plant);

22 (59) [4-methyl-n-ethylcathinone (4-MEC)]  
 23 4-METHYL-*N*-ETHYLCATHINONE (4-MEC);

24 (60) [4-methyl-alpha-pyrrolidinopropiophenone (4-MEPPP)]  
 25 4-METHYL-ALPHA-PYRROLIDINOPROPIOPHENONE (4-MEPPP);

26 (61) [alpha-pyrrolidinopentiophenone (A-PVP)]  
 27 ALPHA-PYRROLIDINOPENTIOPHENONE (ALPHA-PVP);

28 (62) 1-(1,3-benzodioxol-5-yl)-2-(methylamino) butan-1-one (butylone);

29 (63) 2-(methylamino)-1-phenylpentan-1-one (pentedrone);

30 (64) 1-(1,3-benzodioxol-5-yl)-2-(methylamino) pentan-1-one (pentylone);

31 (65) [4-fluoro-n-methylcathinone (flephedrone)]  
 32 4-FLUORO-*N*-METHYLCATHINONE (FLEPHEDRONE);

1 (66) [3-fluoro-*n*-methylcathinone (3-FMC)]  
 2 **3-FLUORO-*N*-METHYLCATHINONE (3-FMC);**

3 (67) [cannabimimetic agents;

4 (68)] 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl)pentan-1-one (naphyrone);  
 5 [and]

6 [(69)] **(68)** [alpha-pyrrolidinobutiophenone (A-PBP)]  
 7 **ALPHA-PYRROLIDINOBUTIOPHENONE (ALPHA-PBP);**

8 **(69)** *N*-(1-AMINO-3-METHYL-1-OXOBUTAN-2-YL)-1-  
 9 **(CYCLOHEXYLMETHYL)-1*H*-INDAZOLE-3-CARBOXAMIDE (AB-CHMINACA);**

10 **(70)** *N*-(1-AMINO-3-METHYL-1-OXOBUTAN-2-YL)-1-PENTYL-1*H*-  
 11 **INDAZOLE-3-CARBOXAMIDE (AB-PINACA);**

12 **(71)** [1-(5-FLUOROPENTYL)-1*H*-INDAZOL-3-YL](NAPHTHALEN-1-  
 13 **YL)METHANONE (THJ-2201); AND**

14 **(72)** *N*-(1-AMINO-3,3-DIMETHYL-1-OXOBUTAN-2-YL)-1-  
 15 **(CYCLOHEXYLMETHYL)-1*H*-INDAZOLE-3-CARBOXAMIDE (MAB-CHMINACA).**

16 [(e) Unless specifically excepted under this subtitle or listed in another schedule,  
 17 any material, compound, mixture, or preparation that contains any quantity of the  
 18 following substances, or that contains their salts, isomers, or salts of isomers, whenever the  
 19 existence of such salts, isomers, or salts of isomers is possible within the specific chemical  
 20 designation, is a substance listed in Schedule I:

21 (1) 5-(1, 1-dimethylheptyl)-2-[(1*r*,3*s*)-3-hydroxycyclohexyl]-phenol  
 22 (cp-47,497);

23 (2) 5-(1,1-dimethyloctyl)-2-[(1*r*,3*s*)-3-hydroxycyclohexyl]-phenol  
 24 (cp-47,497 c8 homologue);

25 (3) 1-pentyl-3-(1-naphthoyl) indole (JWH-018 and AM678)

26 (4) 1-butyl-3-(1-naphthoyl) indole (JWH-073);

27 (5) 1-hexyl-3-(1-naphthoyl) indole (JWH-019);

28 (6) 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl) indole (JWH-200);

29 (7) 1-pentyl-3-(2-methoxyphenylacetyl) indole (JWH-250);

- 1 (8) 1-pentyl-3-(1-(4-methoxynaphthoyl) indole (JWH-081);
- 2 (9) 1-pentyl-3-(4-methyl-1-naphthoyl) indole (JWH-122);
- 3 (10) 1-pentyl-3-(4-chloro-1-naphthoyl) indole (JWH-398);
- 4 (11) 1-(5-fluoropentyl)-3-(1-naphthoyl) indole (AM2201);
- 5 (12) 1-(5-fluoropentyl)-3-(2-iodobenzoyl) indole (AM694);
- 6 (13) 1-pentyl-3-[(4-methoxy)-benzoyl] indole (SR-19 and RCS-4);
- 7 (14) 1-cyclohexylethyl-3-(2-methoxyphenylacetyl) indole (SR-18 and  
8 RCS-8); and
- 9 (15) 1-pentyl-3-(2-chlorophenylacetyl) indole (JWH-203).]

10 [(f)] (E) Unless specifically excepted under this subtitle or listed in another  
11 schedule, a material, compound, mixture, or preparation that contains any quantity of the  
12 following substances having depressant effects on the central nervous system, or that  
13 contains its salts, isomers, or salts of isomers, whenever the existence of such salts, isomers,  
14 or salts of isomers is possible within the specific chemical designation, is a substance listed  
15 in Schedule I:

- 16 (1) [mecloqualone;
- 17 (2) methaqualone; and
- 18 (3)] gamma-hydroxybutyric acid **(GHB)**;
- 19 **(2) MECLOQUALONE; AND**
- 20 **(3) METHAQUALONE.**

21 [(g)] (F) Unless specifically excepted or listed in another schedule, any material,  
22 compound, mixture, or preparation that contains any quantity of the following substances  
23 having a stimulant effect on the central nervous system, or that contains its salts, isomers,  
24 or salts of isomers, is a substance listed in Schedule I:

- 25 (1) aminorex;
- 26 (2) [n-benzylpiperazine] **N-BENZYLPIPERAZINE (BZP)**;
- 27 (3) cathinone;
- 28 (4) fenethylamine;

1 (5) methcathinone;

2 (6) [4-methylaminorex;

3 (7) (±)CIS-4-methylaminorex] (±)CIS-4-METHYLAMINOREX  
4 ((±)CIS-4,5-DIHYDRO-4-METHYL-5-PHENYL-2-OXAZOLAMINE);

5 [(8) (7) [n-ethylamphetamine] N-ETHYLAMPHETAMINE; and

6 [(9) (8) [n, n-dimethylamphetamine] N,  
7 N-DIMETHYLAMPHETAMINE.

8 (G) UNLESS SPECIFICALLY EXCEPTED UNDER THIS SUBTITLE OR LISTED IN  
9 ANOTHER SCHEDULE, ANY MATERIAL, COMPOUND, MIXTURE, OR PREPARATION  
10 THAT CONTAINS ANY QUANTITY OF THE FOLLOWING SUBSTANCES, OR THAT  
11 CONTAINS THEIR SALTS, ISOMERS, OR SALTS OF ISOMERS, WHENEVER THE  
12 EXISTENCE OF SUCH SALTS, ISOMERS, OR SALTS OF ISOMERS IS POSSIBLE WITHIN  
13 THE SPECIFIC CHEMICAL DESIGNATION, IS A SUBSTANCE LISTED IN SCHEDULE I:

14 (1) 5-(1, 1-DIMETHYLHEPTYL)-2-[(1R,3S)-3-  
15 HYDROXYCYCLOHEXYL]-PHENOL (CP-47,497);

16 (2) 5-(1,1-DIMETHYLOCTYL)-2-[(1R,3S)-3-  
17 HYDROXYCYCLOHEXYL]-PHENOL (CP-47,497 C8 HOMOLOG);

18 (3) 1-PENTYL-3-(1-NAPHTHOYL) INDOLE (JWH-018 AND AM678);

19 (4) 1-BUTYL-3-(1-NAPHTHOYL) INDOLE (JWH-073);

20 (5) 1-HEXYL-3-(1-NAPHTHOYL) INDOLE (JWH-019);

21 (6) 1-[2-(4-MORPHOLINYL)ETHYL]-3-(1-NAPHTHOYL) INDOLE  
22 (JWH-200);

23 (7) 1-PENTYL-3-(2-METHOXYPHENYLACETYL) INDOLE (JWH-250);

24 (8) 1-PENTYL-3-[1-(4-METHOXYNAPHTHOYL)] INDOLE (JWH-081);

25 (9) 1-PENTYL-3-(4-METHYL-1-NAPHTHOYL) INDOLE (JWH-122);

26 (10) 1-PENTYL-3-(4-CHLORO-1-NAPHTHOYL) INDOLE (JWH-398);

27 (11) 1-(5-FLUOROPENTYL)-3-(1-NAPHTHOYL) INDOLE (AM2201);

1           **(12) 1-(5-FLUOROPENTYL)-3-(2-IODOBENZOYL) INDOLE (AM694);**

2           **(13) 1-PENTYL-3-[(4-METHOXY)-BENZOYL] INDOLE (SR-19 AND**  
3 **RCS-4);**

4           **(14) 1-CYCLOHEXYLETHYL-3-(2-METHOXYPHENYLACETYL) INDOLE**  
5 **7008 (SR-18 AND RCS-8); AND**

6           **(15) 1-PENTYL-3-(2-CHLOROPHENYLACETYL) INDOLE (JWH-203).**

7           (h) (1) In this subsection:

8                   (i) “controlled dangerous substance analogue” means a substance:

9                               1. that has a chemical structure substantially similar to the  
10 chemical structure of a controlled dangerous substance listed in Schedule I or Schedule II;  
11 and

12                               2. that has a stimulant, depressant, or hallucinogenic effect  
13 on the central nervous system that is substantially similar to or greater than the stimulant,  
14 depressant, or hallucinogenic effect on the central nervous system of a controlled dangerous  
15 substance listed in Schedule I or Schedule II; but

16                   (ii) “controlled dangerous substance analogue” does not include:

17                               1. a controlled dangerous substance;

18                               2. a substance for which there is an approved new drug  
19 application; or

20                               3. a substance exempted for investigational use under § 506  
21 of the Federal Food, Drug, and Cosmetic Act.

22           (2) To the extent intended for human consumption, each controlled  
23 dangerous substance analogue is a substance listed in Schedule I.

24           (i) The Department may not add a substance to Schedule I under § 5-202 of this  
25 title unless the Department finds:

26                   (1) a high potential for abuse of the substance;

27                   (2) no accepted medical use in the United States for the substance; and

28                   (3) a lack of accepted safety for use of the substance under medical  
29 supervision.

1 5-403.

2 (a) Schedule II consists of each controlled dangerous substance:

3 (1) listed in this section;

4 (2) added to Schedule II by the Department under § 5-202(b) of this title;  
5 or

6 (3) designated as a Schedule II controlled dangerous substance by the  
7 federal government unless the Department objects under § 5-202(f) of this title.

8 (b) **UNLESS SPECIFICALLY EXCEPTED OR UNLESS LISTED IN ANOTHER**  
9 **SCHEDULE, ANY OF THE FOLLOWING SUBSTANCES WHETHER PRODUCED DIRECTLY**  
10 **OR INDIRECTLY BY EXTRACTION FROM SUBSTANCES OF VEGETABLE ORIGIN, OR**  
11 **INDEPENDENTLY BY MEANS OF CHEMICAL SYNTHESIS, OR BY A COMBINATION OF**  
12 **EXTRACTION AND CHEMICAL SYNTHESIS:**

13 (1) [Unless the substance is listed in another schedule and except as  
14 provided in paragraph (2) of this subsection, opium and opiate, and a salt, compound,  
15 derivative, or preparation of opium or opiate is a substance listed in Schedule II, including]  
16 **OPIUM AND OPIATE, AND ANY SALT, COMPOUND, DERIVATIVE, OR PREPARATION OF**  
17 **OPIUM OR OPIATE EXCLUDING APOMORPHINE, THEBAIN-DERIVED BUTORPHANOL,**  
18 **DEXTRORPHAN, NALBUPHINE, NALDEMEDINE, NALMEFENE, NALOXEGOL,**  
19 **NALOXONE, AND NALTREXONE, AND THEIR RESPECTIVE SALTS, BUT INCLUDING THE**  
20 **FOLLOWING:**

21 (i) [raw opium] **CODEINE;**

22 (ii) [opium extracts] **DIHYDROETORPHINE;**

23 (iii) [opium fluid extract] **ETHYLMORPHINE;**

24 (iv) [opium fluid] **ETORPHINE HYDROCHLORIDE;**

25 (v) [powdered] **GRANULATED** opium;

26 (vi) [granulated opium] **HYDROCODONE;**

27 (vii) [tincture of opium] **HYDROMORPHINE;**

28 (viii) [codeine] **METOPON;**

29 (ix) [dextropropoxyhene bulk (nondosage form)] **MORPHINE;**

- 1 (x) [dihydroetorphine] OPIUM EXTRACTS;  
2 (xi) [ethylmorphine] OPIUM FLUID;  
3 (xii) [etorphine hydrochloride] ORIPAVINE;  
4 (xiii) [hydrocodone] OXYCODONE;  
5 (xiv) [hydromorphone] OXYMORPHONE;  
6 (xv) [metopon] POWDERED OPIUM;  
7 (xvi) [morphine] RAW OPIUM;  
8 (xvii) [oripavine] THEBAINE; AND  
9 (xviii) [oxycodone;  
10 (xix) oxymorphone; and  
11 (xx) thebaine.] TINCTURE OF OPIUM;

12 [(2) Apomorphine, dextrorphan, nalbuphine, naloxone, and naltrexone, and  
13 their respective salts, are not substances listed in Schedule II.]

14 **(2) ANY SALT, COMPOUND, DERIVATIVE, OR PREPARATION THEREOF**  
15 **WHICH IS CHEMICALLY EQUIVALENT OR IDENTICAL WITH ANY OF THE SUBSTANCES**  
16 **REFERRED TO IN ITEM (1) OF THIS SUBSECTION, EXCEPT THAT THESE SUBSTANCES**  
17 **MAY NOT INCLUDE THE ISOQUINOLINE ALKALOIDS OF OPIUM;**

18 [(3) Substances listed in Schedule II also include:

19 (i) except for the isoquinoline alkaloids of opium, a salt, compound,  
20 derivative, or preparation that is chemically equivalent or identical to a substance listed in  
21 paragraph (1) of this subsection;]

22 [(ii) (3) opium poppy[,] AND poppy straw[, and poppy straw  
23 concentrate];

24 [(iii) (4) coca [leaf] LEAVES AND ANY SALT, COMPOUND,  
25 DERIVATIVE, OR PREPARATION OF COCA LEAVES, INCLUDING COCAINE AND  
26 ECGONINE AND THEIR SALTS, ISOMERS, DERIVATIVES AND SALTS OF ISOMERS AND  
27 DERIVATIVES, AND ANY SALT, COMPOUND, DERIVATIVE, OR PREPARATION THEREOF  
28 WHICH IS CHEMICALLY EQUIVALENT OR IDENTICAL WITH ANY OF THESE

1 SUBSTANCES, EXCEPT THAT THE SUBSTANCES MAY NOT INCLUDE:

2 (I) DECOCAINIZED COCA LEAVES OR EXTRACTION OF  
3 COCA LEAVES, WHICH EXTRACTIONS DO NOT CONTAIN COCAINE OR ECGONINE; OR

4 (II) [<sup>123</sup>I]IOFLUPANE; AND

5 [(iv) cocaine, its salts, optical and geometric isomers, and salts of  
6 isomers;

7 (v) ecgonine, its derivatives, their salts, isomers, and salts of  
8 isomers; and

9 (vi) a compound, mixture, or preparation that contains any of the  
10 substances listed in this section.

11 (4) A substance that is listed in Schedule II is included whether produced:

12 (i) directly or indirectly by extraction from substances of vegetable  
13 origin;

14 (ii) independently by chemical synthesis; or

15 (iii) by a combination of extraction and chemical synthesis]

16 (5) CONCENTRATE OF POPPY STRAW (THE CRUDE EXTRACT OF POPPY  
17 STRAW IN EITHER LIQUID, SOLID, OR POWDER FORM WHICH CONTAINS THE  
18 PHENANTHRENE ALKALOIDS OF THE OPIUM POPPY).

19 (c) [(1) These opiates are substances listed in Schedule II] UNLESS  
20 SPECIFICALLY EXCEPTED OR UNLESS IN ANOTHER SCHEDULE ANY OF THE  
21 FOLLOWING OPIATES, INCLUDING ITS ISOMERS, ESTERS, ETHERS, SALTS, AND SALTS  
22 OF ISOMERS, ESTERS, AND ETHERS WHENEVER THE EXISTENCE OF SUCH ISOMERS,  
23 ESTERS, ETHERS, AND SALTS IS POSSIBLE WITHIN THE SPECIFIC CHEMICAL  
24 DESIGNATION, DEXTROPHAN AND LEVOPROPOXYPHENE EXCEPTED:

25 [(i)] (1) alfentanil;

26 [(ii)] (2) alphaprodine;

27 [(iii)] (3) anileridine;

28 [(iv)] (4) bezitramide;

29 [(v)] (5) BULK DEXTROPROPOXYPHENE (NON-DOSAGE

1 **FORMS);**

2 (6) carfentanil;

3 [(vi)] (7) dihydrocodeine;

4 [(vii)] (8) diphenoxylate;

5 [(viii) dronabinol (in oral solution);]

6 [(ix)] (9) fentanyl;

7 [(x)] (10) isomethadone;

8 [(xi)] (11) [levoalphacetylmethadol]

9 **LEVO-ALPHACETYLMETHADOL;**

10 [(xii)] (12) levomethorphan;

11 [(xiii)] (13) levorphanol;

12 [(xiv)] (14) metazocine;

13 [(xv)] (15) methadone;

14 [(xvi)] (16) methadone – intermediate, 4-cyano-2-dimethylamino-4,  
15 4-diphenyl butane;16 [(xvii)] (17) [moramide – intermediate, 2-methyl-3- morpholino-1,  
17 1-diphenyl-propane-carboxylic acid] **MORAMIDE – INTERMEDIATE,**  
18 **2-METHYL-3- MORPHOLINO-1, 1-DIPHENYLPROPANE-CARBOXYLIC ACID;**19 [(xviii)] (18) pethidine (**MEPERIDINE**);20 [(xix)] (19) pethidine – intermediate – A,  
21 4-cyano-1-methyl-4-phenylpiperidine;22 [(xx)] (20) pethidine – intermediate – B,  
23 ethyl-4-phenylpiperidine-4-carboxylate;24 [(xxi)] (21) pethidine – intermediate – C,  
25 1-methyl-4-phenylpiperidine-4-carboxylic acid;

26 [(xxii)] (22) phenazocine;

- 1 [(xxiii)] **(23)** piminodine;
- 2 [(xxiv)] **(24)** racemethorphan;
- 3 [(xxv)] **(25)** racemorphan;
- 4 [(xxvi)] **(26)** remifentanil;
- 5 [(xxvii)] **(27)** sulfentanil;
- 6 [(xxviii)] **(28)** tapentadol; and
- 7 [(xxix)] **(29)** thiafentanil.

8 [(2) Unless specifically excepted under this subtitle, an isomer, ester, ether,  
9 or salt of an opiate and a salt of an isomer, ester, or ether is a substance listed in Schedule  
10 II if the existence of the isomer, ester, ether, or salt is possible within the specific chemical  
11 designation.]

12 (d) **[A] UNLESS SPECIFICALLY EXCEPTED UNDER THIS SUBTITLE OR LISTED**  
13 **IN ANOTHER SCHEDULE, A** substance is listed in Schedule II if the substance includes a  
14 material, compound, mixture, or preparation that contains any quantity of the following  
15 substances having a potential for abuse associated with a stimulant effect on the central  
16 nervous system:

17 (1) amphetamine, its salts, optical isomers, and salts of its optical isomers;

18 (2) **METHAMPHETAMINE, ITS SALTS, ISOMER, AND SALTS OF**  
19 **ISOMERS;**

20 (3) phenmetrazine and its salts;

21 [(3) a substance that contains any methamphetamine, including salts,  
22 optical isomers, and salts of its optical isomers, in combination with one or more active  
23 nonnarcotic ingredients in recognized therapeutic amounts;]

24 (4) methylphenidate; **AND**

25 (5) [methamphetamine, its salts, optical isomers, and salts of optical  
26 isomers; and

27 (6)] lisdexamfetamine, its salts, isomers, and salts of isomers.

28 (e) [(1) Unless specifically excepted under this subtitle or listed in another  
29 schedule, a substance is listed in Schedule II if the substance includes a material,

1 compound, mixture, or preparation that contains any quantity of the following substances  
2 having a depressant effect on the central nervous system, **INCLUDING ITS SALTS,**  
3 **ISOMERS, AND SALTS OF ISOMERS WHENEVER THE EXISTENCE OF SUCH SALTS,**  
4 **ISOMERS, AND SALTS OF ISOMERS IS POSSIBLE WITHIN THE SPECIFIC CHEMICAL**  
5 **DESIGNATION:**

- 6                    [(i) (1)        amobarbital;
- 7                    [(ii) (2)        glutethimide;
- 8                    [(iii) secobarbital;]
- 9                    [(iv) (3)        pentobarbital;
- 10                   [(v) (4)        phencyclidine; AND
- 11                   [(vi) 1-(1-phenylcyclohexyl) piperidine;
- 12                   (vii) 1-phenylcyclohexylamine; and
- 13                   (viii) 1-piperidinocyclohexanecarbonitrile]

14                    **(5)        SECOBARBITAL.**

15                    [(2)        Unless specifically excepted under this subtitle or listed in another  
16 schedule, a salt, isomer, or salt of an isomer of a substance listed in this subsection is  
17 included in Schedule II if the existence of the salt, isomer, or salt of an isomer is possible  
18 within the specific chemical designation.]

19                    **(F)        AS LISTED IN SCHEDULE II UNDER TITLE 21 OF THE CODE OF FEDERAL**  
20 **REGULATIONS:**

21                    **(1)        NABILONE; AND**

22                    **(2)        DRONABINOL [(-)-DELTA-9-TRANS TETRAHYDROCANNABINOL]**  
23 **IN AN ORAL SOLUTION IN A DRUG PRODUCT APPROVED FOR MARKETING BY THE**  
24 **UNITED STATES FOOD AND DRUG ADMINISTRATION.**

25                    **(G)        UNLESS SPECIFICALLY EXCEPTED OR UNLESS LISTED IN ANOTHER**  
26 **SCHEDULE, ANY MATERIAL, COMPOUND, MIXTURE, OR PREPARATION WHICH**  
27 **CONTAINS ANY QUANTITY OF THE FOLLOWING SUBSTANCES:**

28                    **(1)        IMMEDIATE        PRECURSOR        TO        AMPHETAMINE        AND**  
29 **METHAMPHETAMINE:**

1 (I) PHENYLACETONE; AND

2 (II) RESERVED;

3 (2) IMMEDIATE PRECURSORS TO PHENCYCLIDINE (PCP):

4 (I) 1-PHENYLCYCLOHEXYLAMINE; AND

5 (II) 1-PIPERIDINOCYCLOHEXANECARBONITRILE (PCC); AND

6 (3) IMMEDIATE PRECURSOR TO FENTANYL:

7 (I) 4-ANILINO-N-PHENETHYLPIPERIDINE (ANPP); AND

8 (II) RESERVED.

9 [(f)] (H) The Department may not add a substance to Schedule II under § 5-202  
10 of this title unless the Department finds:

11 (1) a high potential for abuse of the substance;

12 (2) currently accepted medical use of the substance in the United States,  
13 or currently accepted medical use with severe restrictions; and

14 (3) evidence that abuse of the substance may lead to severe psychological  
15 or physical dependence.

16 5-404.

17 (a) Schedule III consists of each controlled dangerous substance **BY WHATEVER**  
18 **OFFICIAL NAME, COMMON OR USUAL NAME, CHEMICAL NAME, OR BRAND NAME**  
19 **DESIGNATED:**

20 (1) listed in this section;

21 (2) added to Schedule III by the Department under § 5-202(b) of this title;  
22 or

23 (3) designated as a Schedule III controlled dangerous substance by the  
24 federal government unless the Department objects under § 5-202(f) of this title.

25 [(b)] (1) Substances listed in Schedule III include:

26 (i) nalorphine; and

1 (ii) except as provided in paragraph (2) of this subsection, an  
2 anabolic steroid consisting of a material, compound, or preparation that includes:

- 3 1. 13beta-ethyl-17beta-hydroxygon-4-en-3-one;
- 4 2. 17alpha-methyl-3alpha,  
5 17beta-dihydroxy-5alpha-androstane;
- 6 3. 17alpha-methyl-3beta, 17beta-dihydroxyandrost-4-ene;
- 7 4. 17alpha-methyl-4-hydroxynandrolone;
- 8 5. 17alpha-methyl-delta1-dihydrotestosterone;
- 9 6. 19-nor-4,9(10)-androstadienedione;
- 10 7. 19-nor-4-androstenediol;
- 11 8. 19-nor-4-androstenedione;
- 12 9. 19-nor-5-androstenediol;
- 13 10. 19-nor-5-androstenedione;
- 14 11. 1-androstenediol;
- 15 12. 1-androstenedione;
- 16 13. 3alpha,17beta-dihydroxy-5-alpha-androstane;
- 17 14. 4-androstenediol (4-AD);
- 18 15. 4-androstenedione;
- 19 16. 4-hydroxy-19-nortestosterone;
- 20 17. 4-hydroxytestosterone;
- 21 18. 5-androstenedione;
- 22 19. bolasterone;
- 23 20. boldenone;
- 24 21. boldione;
- 25 22. calusterone;

- 1 23. chlorotestosterone;
- 2 24. clostebol;
- 3 25. dehydrochlormethyltestosterone;
- 4 26. desoxymethyltestosterone;
- 5 27. dihydrotestosterone;
- 6 28. drostanolone;
- 7 29. ethylestroenol;
- 8 30. fluoxymesterone;
- 9 31. formobulone;
- 10 32. furazabol;
- 11 33. mesterolone;
- 12 34. methandienone;
- 13 35. methandranone;
- 14 36. methandriol;
- 15 37. methandrostenolone;
- 16 38. methasterone;
- 17 39. methenolone;
- 18 40. methyldienolone;
- 19 41. methyltestosterone;
- 20 42. methyltrienolone;
- 21 43. mibolerone;
- 22 44. nandrolone;
- 23 45. norclostebol;

- 1 46. norethandrolone;  
2 47. normethandrolone;  
3 48. oxandrolone;  
4 49. oxymesterone;  
5 50. oxymetholone;  
6 51. prostanazol;  
7 52. stanolone;  
8 53. stanozolol;  
9 54. stenbolone;  
10 55. testolactone;  
11 56. testosterone;  
12 57. tetrahydrogestrinone;  
13 58. trenbolone; and  
14 59. any isomer, ester, salt, or derivative of a substance listed  
15 in this paragraph.

16 (2) The following substances are not included in Schedule III:

17 (i) an estrogen, progestin, or corticosteroid; or

18 (ii) a substance covered by paragraph (1) of this subsection if:

19 1. expressly intended for administration through implants to  
20 cattle or other nonhuman species; and

21 2. approved for that use by the Food and Drug  
22 Administration.]

23 [(c)] (B) (1) Unless **SPECIFICALLY EXCEPTED OR** listed in another  
24 schedule, a substance is listed in Schedule III if the substance includes a material,  
25 compound, mixture, or preparation that contains any quantity of the following substances  
26 having a stimulant effect on the central nervous system:

27 (i) **THOSE COMPOUNDS, MIXTURES, OR PREPARATIONS IN**

1 DOSAGE UNIT FORM CONTAINING ANY STIMULANT SUBSTANCES LISTED IN  
2 SCHEDULE II, WHICH COMPOUNDS, MIXTURES, OR PREPARATIONS WERE LISTED ON  
3 AUGUST 25, 1971, AS EXCEPTED COMPOUNDS UNDER § 1308.32 OF THE CODE OF  
4 FEDERAL REGULATIONS, AND ANY OTHER DRUG OF THE QUANTITATIVE  
5 COMPOSITION SHOWN IN THAT LIST FOR THOSE DRUGS OR THAT IS THE SAME  
6 EXCEPT THAT IT CONTAINS A LESSER QUANTITY OF CONTROLLED SUBSTANCES;

7 (II) benzphetamine;

8 [(ii)] (III) chlorphentermine;

9 [(iii)] (IV) clortermine;

10 [(iv) mazindol;] and

11 (v) phendimetrazine.

12 (2) Subject to paragraph (3) of this subsection, substances in Schedule III  
13 include:

14 (i) a salt of a substance listed in this subsection;

15 (ii) an optical, position, or geometric isomer of a substance listed in  
16 this subsection; or

17 (iii) a salt of an isomer of a substance listed in this subsection.

18 (3) Unless listed in another schedule, a salt, isomer, or salt of an isomer  
19 described in paragraph (2) of this subsection may be included in Schedule III only if the  
20 existence of the salts, isomers, and salts of isomers is possible within the specific chemical  
21 designation.

22 [(d)] (C) Unless listed in another schedule, a substance is listed in Schedule III  
23 if the substance includes a material, compound, mixture, or preparation that contains any  
24 quantity of the following substances having a potential for abuse associated with a  
25 depressant effect on the central nervous system:

26 (1) ANY COMPOUND, MIXTURE, OR PREPARATION CONTAINING:

27 (I) AMOBARBITAL;

28 (II) SECOBARBITAL;

29 (III) PENTOBARBITAL; OR

1 (IV) ANY SALT THEREOF AND ONE OR MORE OTHER ACTIVE  
2 MEDICINAL INGREDIENTS THAT ARE NOT LISTED IN ANY SCHEDULE;

3 (2) ANY SUPPOSITORY DOSAGE FORM CONTAINING:

4 (I) AMOBARBITAL;

5 (II) SECOBARBITAL;

6 (III) PENTOBARBITAL; OR

7 (IV) ANY SALT OF ANY OF THESE DRUGS AND APPROVED BY THE  
8 U.S. FOOD AND DRUG ADMINISTRATION FOR MARKETING ONLY AS A SUPPOSITORY;

9 [(1)] (3) except those substances that are specifically listed in other  
10 schedules, a substance that contains any quantity of a derivative of barbituric acid, [or] a  
11 salt of a derivative of a barbituric [acid];

12 (2) aprobarbital;

13 (3) butabarbital (secbutabarbital);

14 [(4)] ACID, OR butalbital [(fiorinal)], INCLUDING, WITH ONE OR MORE  
15 ACTIVE, NONNARCOTIC INGREDIENTS IN RECOGNIZED THERAPEUTIC AMOUNTS,  
16 (FIORICET) AND (FIORINAL);

17 [(5) butobarbital (butethal);]

18 [(6)] (4) chlorhexadol;

19 [(7)] (5) embutramide;

20 [(8) gamma hydroxybutyric acid preparations;]

21 (6) ANY DRUG PRODUCT CONTAINING GAMMA HYDROXYBUTYRIC  
22 ACID, INCLUDING ITS SALTS, ISOMERS, AND SALTS OF ISOMERS, FOR WHICH AN  
23 APPLICATION IS APPROVED UNDER SECTION 505 OF THE FEDERAL FOOD, DRUG,  
24 AND COSMETIC ACT;

25 (7) KETAMINE, ITS SALTS, ISOMERS, AND SALTS OF ISOMERS;

26 [(9)] (8) lysergic acid;

27 [(10)] (9) lysergic acid amide;

1            [(11)] (10) methyprylon;

2            [(12) pentazocine;]

3            [(13)] (11) perampanel, AND ITS SALTS, ISOMERS, AND SALTS OF  
4 ISOMERS (FYCOMPA);

5            [(14)] (12) sulfondiethylmethane;

6            [(15)] (13) sulfonethylmethane;

7            [(16)] (14) sulfonmethane; AND

8            [(17) talbutal;

9            (18) thiamylal;

10           (19) thiopental; and

11           (20) vinbarbital.]

12            (15) TILETAMINE AND ZOLAZEPAM OR ANY SALT THEREOF, INCLUDING  
13 A TILETAMINE–ZOLAZEPAM COMBINATION PRODUCT (TRADE NAME TELAZOL).

14            (D) AS LISTED IN SCHEDULE III UNDER TITLE 21 OF THE CODE OF  
15 FEDERAL REGULATIONS, NALORPHINE 9400.

16            (e) UNLESS SPECIFICALLY EXCEPTED OR UNLESS LISTED IN ANOTHER  
17 SCHEDULE:

18            (1) [Substances] SUBSTANCES listed in Schedule III include [a] ANY  
19 material, compound, mixture, or preparation [that contains limited quantities of any of  
20 these narcotic drugs or their salts] CONTAINING ANY OF THE FOLLOWING NARCOTIC  
21 DRUGS, OR THEIR SALTS CALCULATED AS THE FREE ANHYDROUS BASE OR  
22 ALKALOID, IN LIMITED QUANTITIES AS SET FORTH BELOW:

23            (i) not more than 1.80 grams of codeine per 100 milliliters or not  
24 more than 90 milligrams per dosage unit, with an equal or greater quantity of an  
25 isoquinoline alkaloid of opium;

26            (ii) not more than 1.80 grams of codeine per 100 milliliters or not  
27 more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients  
28 in recognized therapeutic amounts;

1 (iii) [not more than 300 milligrams of dihydrocodeinone per 100  
2 milliliters or not more than 15 milligrams per dosage unit, with a fourfold or greater  
3 quantity of an isoquinoline alkaloid of opium;

4 (iv) not more than 300 milligrams of dihydrocodeinone per 100  
5 milliliters or not more than 15 milligrams per dosage unit, with one or more active,  
6 nonnarcotic ingredients in recognized therapeutic amounts;

7 (v)] not more than 1.80 grams of dihydrocodeine per 100 milliliters  
8 or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic  
9 ingredients in recognized therapeutic amounts;

10 [(vi)] (IV) not more than 300 milligrams of ethylmorphine per 100  
11 milliliters or not more than 15 milligrams per dosage unit, with one or more active,  
12 nonnarcotic ingredients in recognized therapeutic amounts;

13 [(vii)] (V) not more than 500 milligrams of opium per 100 milliliters  
14 or per 100 grams, or not more than 25 milligrams per dosage unit, with one or more active,  
15 nonnarcotic ingredients in recognized therapeutic amounts;

16 [(viii)] (VI) not more than 100 milligrams of opium per 100 milliliters  
17 or per 100 grams, or not more than 5 milligrams per dosage unit; AND

18 [(ix)] (VII) not more than 50 milligrams of morphine per 100  
19 milliliters or per 100 grams with one or more active, nonnarcotic ingredients in recognized  
20 therapeutic amounts[; and

21 (x) buprenorphine].

22 [(2) Substances listed in Schedule III include a compound, mixture, or  
23 preparation or salt of a compound, mixture, or preparation and another active medicinal  
24 ingredient that is not listed in another schedule and that contains:

25 (i) amobarbital;

26 (ii) secobarbital; or

27 (iii) pentobarbital.]

28 (2) ANY MATERIAL, COMPOUND, MIXTURE, OR PREPARATION  
29 CONTAINING ANY OF THE FOLLOWING NARCOTIC DRUGS OR THEIR SALTS, AS SET  
30 FORTH BELOW:

31 (I) BUPRENORPHINE; AND

1 (II) RESERVED.

2 (3) [If] IF not combined with one or more active medicinal ingredients that  
3 are listed in another schedule, substances listed in Schedule III include a suppository  
4 dosage form or salt of a suppository dosage that contains:

5 (i) amobarbital;

6 (ii) secobarbital; or

7 (iii) pentobarbital.

8 (f) (1) EXCEPT AS PROVIDED IN PARAGRAPH (2) OF THIS SUBSECTION,  
9 AN ANABOLIC STEROID CONSISTING OF ANY MATERIAL, COMPOUND, MIXTURE, OR  
10 PREPARATION CONTAINING ANY QUANTITY OF THE FOLLOWING SUBSTANCES,  
11 INCLUDING ITS SALTS, ESTERS, AND ETHERS:

12 (I) 3BETA,17-DIHYDROXY-5A-ANDROSTANE;

13 (II) 3ALPHA,17BETA-DIHYDROXY-5A-ANDROSTANE;

14 (III) 5 ALPHA-ANDROSTAN-3,17-DIONE;

15 (IV) 1-ANDROSTENEDIOL  
16 (3BETA,17BETA-DIHYDROXY-5ALPHA-ANDROST-1-ENE);

17 (V) 1-ANDROSTENEDIOL  
18 (3ALPHA,17BETA-DIHYDROXY-5ALPHA-ANDROST-1-ENE);

19 (VI) 4-ANDROSTENEDIOL  
20 (3BETA,17BETA-DIHYDROXY-ANDROST-4-ENE);

21 (VII) 5-ANDROSTENEDIOL  
22 (3BETA,17BETA-DIHYDROXY-ANDROST-5-ENE);

23 (VIII) 1-ANDROSTENEDIONE;

24 (IX) 4-ANDROSTENEDIONE;

25 (X) 5-ANDROSTENEDIONE;

26 (XI) BOLASTERONE;

27 (XII) BOLDENONE;

- 1 (XIII) BOLDIONE;
- 2 (XIV) CALUSTERONE;
- 3 (XV) CHLOROTESTOSTERONE (CLOSTEBOL);
- 4 (XVI) DEHYDROCHLOROMETHYLTESTOSTERONE;
- 5 (XVII) DESOXYMETHYLTESTOSTERONE;
- 6 (XVIII) DELTA1-DIHYDROTESTOSTERONE  
7 (17BETA-HYDROXY-5ALPHA-ANDROST-1-EN-3-ONE);
- 8 (XIX) DIHYDROTESTOSTERONE (4-DIHYDROTESTOSTERONE)  
9 (17BETA-HYDROXY-ANDROSTAN-3-ONE) (STANOLONE);
- 10 (XX) DROSTANOLONE;
- 11 (XXI) ETHYLESTRENOL;
- 12 (XXII) FLUOXYMESTERONE;
- 13 (XXIII) FORMEBOLONE;
- 14 (XXIV) FURAZABOL;
- 15 (XXV) 13BETA-ETHYL-17BETA-HYDROXYGON-4-EN-3-ONE;
- 16 (XXVI) 4-HYDROXYTESTOSTERONE;
- 17 (XXVII) 4-HYDROXY-19-NORTESTOSTERONE;
- 18 (XXVIII) MESTANOLONE  
19 (17ALPHA-METHYL-17BETA-HYDROXY-5-ANDROSTAN-3-ONE);
- 20 (XXIX) MESTEROLONE;
- 21 (XXX) METHANDIENONE (METHANDROSTENOLONE)  
22 (17ALPHA-METHYL-17BETA-HYDROXYANDROST-1,4-DIEN-3-ONE);
- 23 (XXXI) METHANDRIOL;

- 1 (XXXII) METHASTERONE;
- 2 (XXXIII) METHENOLONE;
- 3 (XXXIV) 17ALPHA-METHYL-3BETA,  
4 17BETA-DIHYDROXY-5A-ANDROSTANE;
- 5 (XXXV) 17ALPHA-METHYL-3ALPHA,  
6 17BETA-DIHYDROXY-5A-ANDROSTANE;
- 7 (XXXVI) 17ALPHA-METHYL-3BETA,  
8 17BETA-DIHYDROXYANDROST-4-ENE;
- 9 (XXXVII) 17ALPHA-METHYL-4-HYDROXYNANDROLONE;
- 10 (XXXVIII) METHYLDIENOLONE;
- 11 (XXXIX) METHYLTRIENOLONE;
- 12 (XL) METHYLTESTOSTERONE;
- 13 (XLI) MIBOLERONE;
- 14 (XLII) 17ALPHA-METHYL-DELTA1-DIHYDROTESTOSTERONE;
- 15 (XLIII) NANDROLONE;
- 16 (XLIV) 19-NOR-4-ANDROSTENEDIOL (3BETA,  
17 17BETA-DIHYDROXYESTR-4-ENE);
- 18 (XLV) 19-NOR-4-ANDROSTENEDIOL (3ALPHA,  
19 17BETA-DIHYDROXYESTR-4-ENE);
- 20 (XLVI) 19-NOR-5-ANDROSTENEDIOL (3BETA,  
21 17BETA-DIHYDROXYESTR-5-ENE);
- 22 (XLVII) 19-NOR-5-ANDROSTENEDIOL (3ALPHA,  
23 17BETA-DIHYDROXYESTR-5-ENE);
- 24 (XLVIII) 19-NOR-4,9(10)-ANDROSTADIENEDIONE;
- 25 (XLIX) 19-NOR-4-ANDROSTENEDIONE;

- 1 (L) 19-NOR-5-ANDROSTENEDIONE;
- 2 (LI) NORBOLETHONE (13BETA,  
3 17ALPHA-DIETHYL-17BETA-HYDROXYGON-4-EN-3-ONE);
- 4 (LII) NORCLOSTEBOL;
- 5 (LIII) NORETHANDROLONE;
- 6 (LIV) NORMETHANDROLONE;
- 7 (LV) OXANDROLONE;
- 8 (LVI) OXYMESTERONE;
- 9 (LVII) OXYMETHOLONE;
- 10 (LVIII) PROSTANOZOL;
- 11 (LIX) STANOZOLOL;
- 12 (LX) STENBOLONE;
- 13 (LXI) TESTOLACTONE;
- 14 (LXII) TESTOSTERONE;
- 15 (LXIII) TETRAHYDROGESTRINONE; AND
- 16 (LXIV) TRENBOLONE.

17 (2) THE FOLLOWING SUBSTANCES ARE NOT INCLUDED IN SCHEDULE  
18 III:

- 19 (I) AN ESTROGEN, PROGESTIN, OR CORTICOSTEROID; OR
- 20 (II) A SUBSTANCE COVERED BY PARAGRAPH (1) OF THIS  
21 SUBSECTION IF:

22 1. EXPRESSLY INTENDED FOR ADMINISTRATION  
23 THROUGH IMPLANTS TO CATTLE OR OTHER NONHUMAN SPECIES; AND



1                   **(2) DEXTROPROPOXYPHENE (ALPHA-(+)-4-DIMETHYLAMINO-1,**  
2 **2-DIPHENYL-3-METHYL-2-PROPIONOXYBUTANE); AND**

3                   **(3) 2-[(DIMETHYLAMINO)METHYL]-1-(3-**  
4 **METHOXYPHENYL)CYCLOHEXANOL, ITS SALTS, OPTICAL AND GEOMETRIC ISOMERS**  
5 **AND SALTS OF THESE ISOMERS (INCLUDING TRAMADOL).**

6           **(C)** Substances listed in Schedule IV include a material, compound, mixture, or  
7 preparation that contains any quantity of the following substances having a potential for  
8 abuse associated with a depressant effect on the central nervous system, **INCLUDING ITS**  
9 **SALTS, ISOMERS, AND SALTS OF ISOMERS WHENEVER THE EXISTENCE OF SUCH**  
10 **SALTS, ISOMERS, AND SALTS OF ISOMERS IS POSSIBLE WITHIN THE SPECIFIC**  
11 **CHEMICAL DESIGNATIONS:**

12                   (1) alfaxalone;

13                   (2) alprazolam;

14                   (3) barbital;

15                   (4) **BREXANOLONE;**

16                   **(5)** bromazepam;

17                   [(5) butorphanol;]

18                   (6) camazepam;

19                   (7) carisoprodol;

20                   (8) [cathine +/- (norpseudoepedrine);

21                   (9)] chloral betaine;

22                   [(10)] **(9)** chloral hydrate;

23                   [(11)] **(10)** chlordiazepoxide;

24                   [(12)] **(11)** clobazam;

25                   [(13)] **(12)** clonazepam;

26                   [(14)] **(13)** clorazepate;

- 1            [(15)] **(14)** clonazepam;
- 2            [(16)] **(15)** clonazepam;
- 3            [(17)] **(16)** delorazepam;
- 4            [(18) dexfenfluramine;
- 5            (19) dextropropoxyphene dosage forms;
- 6            (20)] **(17)** diazepam;
- 7            [(21)] **(18)** dichloralphenazone;
- 8            [(22) eluxadoline (viberzi);
- 9            (23)] **(19)** estazolam;
- 10           [(24)] **(20)** ethchlorvynol;
- 11           [(25)] **(21)** ethinamate;
- 12           [(26)] **(22)** [ethylloflazepate] **ETHYL LOFLAZEPATE;**
- 13           [(27) fencamfamin;
- 14           (28) fenproporex;]
- 15           [(29)] **(23)** fludiazepam;
- 16           [(30)] **(24)** flunitrazepam;
- 17           [(31)] **(25)** flurazepam;
- 18           **(26) FOSPROPOFOL;**
- 19           [(32)] **(27)** halazepam;
- 20           [(33)] **(28)** haloxazolam;
- 21           [(34)] **(29)** ketazolam;
- 22           [(35)] **(30)** lorazepam;
- 23           [(36)] **(31)** lorazepam;

- 1            [(37) (32) lormetazepam;
- 2            [(38) (33) mebutamate;
- 3            [(39) (34) medazepam;
- 4            [(40) mefenorex;]
- 5            [(41) (35) [methohexital] MEPROBAMATE;
- 6            [(42) (36) [meprobamate] METHOHEXITAL;
- 7            [(43) (37) methylphenobarbital (MEPHOBARBITAL);
- 8            [(44) (38) midazolam;
- 9            [(45) modafinil;]
- 10           [(46) (39) nimetazepam;
- 11           [(47) (40) [nitrozepam] NITRAZEPAM;
- 12           [(48) (41) nordiazepam;
- 13           [(49) (42) oxazepam;
- 14           [(50) (43) oxazolam;
- 15           [(51) (44) paraldehyde;
- 16           [(52) (45) petrichloral;
- 17           [(53) (46) phenobarbital;
- 18           [(54) (47) pinazepam;
- 19           [(55) pipradrol;]
- 20           [(56) (48) prazepam;
- 21           [(57) (49) quazepam;
- 22           [(58) sibutramine;]

- 1            [(59) SPA (lefetamine);
- 2            (60)] **(50)**    suvorexant [(belsomra)] **(BELSOMRA)**;
- 3            [(61)] **(51)**    temazepam;
- 4            [(62)] **(52)**    tetrazepam;
- 5            [(63) tramadol;]
- 6            [(64)] **(53)**    triazolam;
- 7            [(65)] **(54)**    zaleplon [(sonata)] **(SONATA)**;
- 8            [(66)] **(55)**    zolpidem [(ambien)] **(AMBIEN)**; and
- 9            [(67)] **(56)**    zopiclone [(lunesta)] **(LUNESTA)**.

10           [(c)] **(D)**    Substances listed in Schedule IV include:

- 11                (1)    a material, compound, mixture, or preparation that contains
- 12    fenfluramine; and
- 13                (2)    if its existence is possible:
- 14                        (i)    a salt of fenfluramine;
- 15                        (ii)   an optical, position, or geometric isomer of fenfluramine,
- 16    **INCLUDING DEXFENFLURAMINE;** and
- 17                        (iii)   a salt of an isomer of fenfluramine.

18           **(E)    SUBSTANCES LISTED IN SCHEDULE IV INCLUDE:**

- 19                **(1)    A MATERIAL, COMPOUND, MIXTURE, OR PREPARATION THAT**
- 20    **CONTAINS LORCASERIN; AND**
- 21                **(2)    IF ITS EXISTENCE IS POSSIBLE:**
- 22                        **(I)    A SALT OF LORCASERIN;**
- 23                        **(II)   AN OPTICAL, POSITION, OR GEOMETRIC ISOMER OF**
- 24    **LORCASERIN; AND**
- 25                        **(III) A SALT OF AN ISOMER OF LORCASERIN.**

1           **[(d)] (F)**       Substances listed in Schedule IV include a material, compound,  
2 mixture, or preparation that contains any quantity of the following substances having a  
3 potential for abuse associated with a stimulant effect on the central nervous system,  
4 **INCLUDING ITS SALTS, ISOMERS, AND SALTS OF ISOMERS:**

5           (1)       **CATHINE ((+)-NORPSEUDOEPHEDRINE);**

6           (2)       diethylpropion;

7           (3)       **FENCAMFAMIN;**

8           (4)       **FENPROPOREX;**

9           (5)       **MAZINDOL;**

10          (6)       **MEFENOREX;**

11          (7)       **MODAFINIL;**

12           **[(2)] (8)**       pemoline, including organometallic complexes and their  
13 chelates; **[and]**

14          **[(3)] (9)**       phentermine;

15          (10)       **PIPRADROL;**

16          (11)       **SIBUTRAMINE;**

17          (12)       **SOLRIAMFETOL (2-AMINO-3-PHENYLPROPYL CARBAMATE;**  
18 **BENZENEPROPANOL, BETA-AMINO-, CARBAMATE (ESTER)); AND**

19          (13)       **SPA ((-)-1-DIMETHYLAMINO- 1,2-DIPHENYLETHANE).**

20           **(G) UNLESS SPECIFICALLY EXCEPTED OR UNLESS LISTED IN ANOTHER**  
21 **SCHEDULE, ANY MATERIAL, COMPOUND, MIXTURE, OR PREPARATION THAT**  
22 **CONTAINS ANY QUANTITY OF THE FOLLOWING SUBSTANCES, INCLUDING ITS SALTS:**

23          (1)       **PENTAZOCINE;**

24          (2)       **BUTORPHANOL (INCLUDING ITS OPTICAL ISOMERS); AND**

25          (3)       **ELUXADOLINE (5-[[[(2S)-2-AMINO-3-[4-AMINOCARBONYL)-2,**  
26 **6-DIMETHYLPHENYL]-1-OXOPROPYL]][(1S)-1-(4-PHENYL-1H-IMIDAZOL-2-**

1 **YL)ETHYL]AMINO]METHYL]-2-METHOXYBENZOIC ACID) (INCLUDING ITS OPTICAL**  
2 **ISOMERS) AND ITS SALTS, ISOMERS, AND SALTS OF ISOMERS.**

3 **[(e) (H)** By regulation, the Department may exempt from this section a  
4 compound, mixture, or preparation that contains a depressant substance listed in  
5 subsection (b) of this section if:

6 (1) the compound, mixture, or preparation contains an active medicinal  
7 ingredient that does not have a depressant effect on the central nervous system; and

8 (2) the admixtures are included in combinations, quantity, proportion, or  
9 concentration that vitiate the potential for abuse of the substances that have a depressant  
10 effect on the central nervous system.

11 **[(f) (I)** The Department may not add a substance to Schedule IV under §  
12 5-202 of this title unless the Department finds that:

13 (1) the substance has a low potential for abuse relative to the substances  
14 listed in Schedule III;

15 (2) the substance has currently accepted medical use in treatment in the  
16 United States; and

17 (3) abuse of the substance may lead to limited physical dependence or  
18 psychological dependence relative to the substances in Schedule III.

19 5-406.

20 (a) Schedule V consists of each controlled dangerous substance:

21 (1) listed in this section;

22 (2) added to Schedule V by the Department under § 5-202(b) of this title;  
23 or

24 (3) designated as a Schedule V controlled dangerous substance by the  
25 federal government unless the Department objects under § 5-202(f) of this title.

26 (b) **[A substance is listed in Schedule V if the substance includes a compound,**  
27 **mixture, or preparation that contains the following narcotic drugs or their salts] UNLESS**  
28 **SPECIFICALLY EXCEPTED OR UNLESS LISTED IN ANOTHER SCHEDULE, ANY**  
29 **MATERIAL, COMPOUND, MIXTURE, OR PREPARATION CONTAINING ANY OF THE**  
30 **FOLLOWING NARCOTIC DRUGS AND THEIR SALTS, AS SET FORTH BELOW:**

31 **(1) RESERVED; AND**

1           **(2) RESERVED.**

2           **(C) ANY COMPOUND, MIXTURE, OR PREPARATION CONTAINING ANY OF THE**  
 3 **FOLLOWING NARCOTIC DRUGS, OR THEIR SALTS CALCULATED AS THE FREE**  
 4 **ANHYDROUS BASE OR ALKALOID, IN LIMITED QUANTITIES AS SET FORTH BELOW,**  
 5 **WHICH SHALL INCLUDE ONE OR MORE NONNARCOTIC ACTIVE MEDICINAL**  
 6 **INGREDIENTS IN SUFFICIENT PROPORTION TO CONFER UPON THE COMPOUND,**  
 7 **MIXTURE, OR PREPARATION VALUABLE MEDICINAL QUALITIES OTHER THAN THOSE**  
 8 **POSSESSED BY NARCOTIC DRUGS ALONE:**

9                   (1)   **[(i)]** not more than 200 milligrams of codeine per 100 milliliters or per  
 10 100 grams;

11                               **[(ii)] (2)** not more than 100 milligrams of dihydrocodeine per 100  
 12 milliliters or per 100 grams;

13                               **[(iii)] (3)** not more than **[50] 100** milligrams of ethylmorphine per  
 14 100 milliliters or per 100 grams;

15                               **[(iv)] (4)** not more than 2.5 milligrams of diphenoxylate and not less  
 16 than 25 micrograms of atropine sulfate per dosage unit; **OR**

17                               **[(v) brivaracetam;]**

18                               **[(vi)] (5)** difenoxin preparations 0.5mg/25ug ATSO4/DU  
 19 (MOTOFEN)[;

20                               (vii) ezogabine (potiga);

21                               (viii) lacosamide (vimpat);

22                               (ix) pregabalin (lyrica); or

23                               (x) pyrovalerone; and

24                   (2) nonnarcotic active medicinal ingredients in sufficient proportion to  
 25 confer on the compound, mixture, or preparation valuable medicinal qualities other than  
 26 those possessed by the narcotic drug alone].

27           **(D) UNLESS SPECIFICALLY EXEMPTED OR EXCLUDED OR UNLESS LISTED IN**  
 28 **ANOTHER SCHEDULE, ANY MATERIAL, COMPOUND, MIXTURE, OR PREPARATION**  
 29 **THAT CONTAINS ANY QUANTITY OF THE FOLLOWING SUBSTANCES HAVING A**  
 30 **STIMULANT EFFECT ON THE CENTRAL NERVOUS SYSTEM, INCLUDING ITS SALTS,**  
 31 **ISOMERS, AND SALTS OF ISOMERS:**

1 (1) PYROVALERONE; AND

2 (2) RESERVED.

3 (E) UNLESS SPECIFICALLY EXEMPTED OR EXCLUDED OR UNLESS LISTED IN  
4 ANOTHER SCHEDULE, ANY MATERIAL, COMPOUND, MIXTURE, OR PREPARATION  
5 THAT CONTAINS ANY QUANTITY OF THE FOLLOWING SUBSTANCES HAVING A  
6 DEPRESSANT EFFECT ON THE CENTRAL NERVOUS SYSTEM, INCLUDING ITS SALTS:

7 (1) BRIVARACETAM

8 ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl] butanamide) (BRIVIACT);

9 (2) EZOGABINE

10 [N-[2-amino-4-(4-fluorobenzylamino)-phenyl]-carbamic acid ethyl  
11 ester] (POTIGA);

12 (3) LACOSAMIDE

13 [(R)-2-acetoamido-N-benzyl-3-methoxy-propionamide] (VIMPAT); AND

14 (4) PREGABALIN [(S)-3-(aminomethyl)-5-methylhexanoic  
15 acid] (LYRICA).

16 (F) A DRUG PRODUCT IN FINISHED DOSAGE FORMULATION THAT HAS BEEN  
17 APPROVED BY THE UNITED STATES FOOD AND DRUG ADMINISTRATION THAT  
18 CONTAINS CANNABIDIOL (2-[1R-3-methyl-6R-(1-methylethenyl)-2-  
19 cyclohexen-1-yl]-5-pentyl-1,3-benzenediol) DERIVED FROM CANNABIS AND  
20 NO MORE THAN 0.1% (W/W) RESIDUAL TETRAHYDROCANNABINOLS.

21 [(c)] (G) The Department may not add a substance to Schedule V under § 5-202  
22 of this title unless the Department finds:

23 (1) the substance has a low potential for abuse relative to the substances  
24 listed in Schedule IV;

25 (2) the substance has currently accepted medical use in the United States;  
26 and

27 (3) abuse of the substance may lead to limited physical dependence or  
28 psychological dependence liability relative to the substances listed in Schedule IV.

29 SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect  
30 October 1, 2020.